



Chronic forms of coronary artery disease




Sepši Milan sepsim@gmail.com



University Hospital Brno, Department of Internal Medicine and Cardiology



CAD is the first cause of death



Murray & Lopez. Lancet. 1997;349:1269-1276



Pathophysiology

Vascular resistance (metabolic control, humoral and neural factors) Coronary blood flow (duration of diastole / pressure gradient) Oxygen demand






Oxygen suply

- Heart rate
- Contractility
- Systolic wall stress





Adapted from Pepine CJ. Am J Cardiol. 1998;82(suppl 104).

Diagnosis

History of patient

- Familiar history
- Personal history
- Sex (M>F), age
- pain
- **Physical examination**
- **Clinical test**

Risk assessment (low, probable, high)







Estimate of CAD Probability (Duke Clinical Score)

- age, gender and pain type were the most powerful predictors
- other predictors
 - smoking (defined as a history of smoking half a pack or more of cigarettes per day within five years of the study or at least 25 pack-years)
 - Q wave or ST-T-wave changes
 - hyperlipidemia (defined as a cholesterol level >250 mg/dL / 6,4 mmol/L)
 - **diabetes** (glucose >140mg/dL / 7,8 mmol/L). Of these risk factors, diabetes had the greatest influence on increasing risk.

Am J Med 1983;75:771-80 ; Am J Med 1990;89:7-14 Ann Intern Med 1993;118:81-90



Estimate of CAD Probability

a 64-year-old man with typical angina has
a ?? 94 Jikelihood of having significant CAD

a 32-year-old woman with nonanginal chest pain has
a ???? % chance of CAD







N Engl J Med 1979;300:1350-8

Risk factors

Major independent risk factors

- Advang
- Tobacc
- Diabete
- Elevate
- Hyperte

Conditiona

- Elevate
- Inflamn
- Prothro
- Small L


Predisposi

- Abdom
- Ethnic
- Family
- Obesity
 - Psycho





Atherosclerosis: a multifactorial disease







Angina pectoris

Typical angina (definite)

- 1. Substernal chest discomfort with a characteristic quality and duration that is
- 2. Provoked by exertion or emotional stress and
- 3. Relieved by rest or nitroglycerin.

Atypical angina (probable)

Noncai

Meet

A pain or discomfort in the chest or adjacent areas caused by insufficient blood flow to the heart muscle.

J Am Coll Cardiol. 1983;1:574, Letter



Pain - descriptio


(1) location

- located substernally or jugar
- Less often over the prec
- Nevertheless can be loc neck; rarely, it may be loc
- radiates down the arms / left side is more common the arm

(2) quality

- deep visceral pressure of stabbing or pinprick-like
- Angina is almost never sl with position or respiration
- (3) duration of the discomfort
 - 10-30 sec plateau and m
- (4) inciting factors
 - physical activity, emotion

(5) factors relieving the pain



Grading of Angina of Effort by the Canadian Cardiovascular Society

- I. "Ordinary physical activity does not cause ... angina," such as walking and climbing stairs. Angina with strenuous or rapid or prolonged exertion at work or recreation.
- II. "Slight limitation of ordinary activity." Walking or climbing stairs rapidly, walking uphill, walking or stair climbing after meals, or in cold, or in wind, or under emotional stress, or only during the few hours after awakening. Walking more than 2 blocks on the level and climbing more than one flight of ordinary stairs at a normal pace and in normal conditions.




III.

IV.

"Marked limitation of ordinary physical activity." Walking one to two blocks on the level and climbing one flight of stairs in normal conditions and at normal pace.

"Inability to carry on any physical activity without discomfort -- anginal syndrome may be present at rest."






Silent ischemia

- Asymptomatic ischemic episodes
- The prevalence : approximates 40 percent in patients with chronic stable angina
- ST-segment depression on ECG monitoring
- Pathophysiology of Silent Ischemia: neuropathy (diabetic patients) or less severe ischemia?























Echocardiography – anterior wall







Courtesy of: MUDr. Jan Maňoušek

Diagnosis – tests II

Exercise ECG stress testing

- Ergometry, treadmill , hand-grip
- Ecg, BP, heart rate
- dificulties in woman

Stress Echocardiography - dobutamine

- (1) decrease in wall motion in one or more LV segments with stress
- (2) diminution in systolic wall thickening in one or more segments during stress, and
- (3) compensatory hyperkinesis in complementary (nonischemic) wall segments



Myocardial Perfusion Imaging

- thallium -201 (201TI); technetium-99m (99mTc)
- single-photon emission computed tomography (SPECT)








Comparison of Stress Tests

meta-analysis on 44 articles (published between 1990 and 1997)



exercise echocardiography had significantly better discriminatory power than exercise myocardial perfusion imaging





JAMA 1998;280:913-20


Diagnosis – coronary angiography

- Who?
 - pain + pathological non-invasive tests
 - Clinical probability (smoker, obesity, familiar history, male)
 - Other problem: heart failure, arrhythmias, unstability
- rationale is to identify high risk patients in whom coronary angiography and subsequent revascularization might improve survival
















Coronary Angiography





FAKULTNÍ NEMOCNICE



Chronic Stable Angina Treatment Objectives

To reduce the risk of mortality and morbid events

To reduce symptoms

- anginal chest pain or exertional dyspnea
- palpitations or syncope
- fatigue, edema or orthopnea







Treatment

Non – pharmacological

- Revascularisation
 - Coronary artery bypass grafting (CABG)
 - percutaneous coronary intervention (PCI, PTCI)
- Heart transplantation
- Pharmacological
 - Betablockers
 - antiplatelet agens
 - Lipid lowering agens
 - angiotensin-converting enzyme inhibitor ACEI
 - Nitroglycerin / nitrates
 - (Calcium antagonist)





Indications of revascularisation

1. To be candidate for revascularization procedure, one must have symptomatic or objective signs of ischemia.

2. Indications for Percutanoues Coronary Intervention (PCI, formerly Percutaneous transluminal coronary angioplasty PTCA) or Coronary Artery Bypass Graft (CABG) may vary from one center to another according to experience, skills and results.



3. Definite indications for CABG: 3 VD with proximal stenosis, LM disease.




4. Definite indications for PCI: SVD (apart from ostial LAD), favourable morphology.



Procedure


- Sheath in femoral, radial or brachial artery
- diameter sheath (usually 6F, but also 5 to 8)
- guiding catheter
- guide wire 0.014 inch
- balloon
- stent







PCI - ACD












Courtesy of: MUDr. Roman Miklík, Ph.D.



Saphenous vein grafts (SVG) are conduits made by harvesting a piece of vein from the patient's leg and attaching it between the aorta and coronary artery



Arterial bypass grafts involve re-routing an artery from its normal course and attaching it to the coronary artery

- Internal Mammary Artery
- Gastroepiploic Artery
 - Radial Artery



Current Medical State of SVG Disease

Average lifespan for a vein graft is 5-10 years

- 50% of SVGs will be occluded within 10 years
- 75% will develop severe narrowing in same period

SVG lesions presenting within the first year after surgery are typically caused by intimal hyperplasia

• respond well to balloon dilatation

Late vein graft stenoses are more commonly caused by diffuse atherosclerosis

 friable plaque and thrombus tend to fragment and embolize into distal coronary vessels







Ischemia Trial 2019

Patients with **stable** ischemic ischemic heart disease and moderate to severe ischemia were randomized to routine **invasive therapy** (n = 2,588) versus **optimal medical therapy** (n = 2,591) Duration of follow-up: 3.3 years Mean patient age: 64 years


Inclusion: Moderate to severe ischemia on noninvasive stress testing







Ischemia Trial





FAKULTNÍ NEMOCNICI BRNO ISCHEMIA trial showed that heart procedures added to taking medicines and making lifestyle changes did not reduce the overall rate of heart attack or death compared with medicines and lifestyle changes alone.

Treatment

Non – pharmacological

- Revascularisation: CABG / PCI
- heart transplantation
- Pharmacological
 - antiplatelet agens
 - Betablockers
 - ACEI
 - Calcium antagonist
 - Lipid lowering agens
 - Nitroglycerin / nitrates







Treatment – antiplatelet agens

Cyclooxygenase inhibitors

Aspirin (Acetylosalicylic acid) 100 mg daily

Adenosine diphosphate (ADP) receptor inhibitors 6-12 month after MI

- Ticagrelor (Brilique)
- Prasugrel (Efient)
- Clopidogrel 75 mg daily
 - (Ticlopidine)







Treatment - betablockers


- Cardioselective
 - Metoprolol: 100-400 mg
 - Atenolol: 50-200 mg
 - Betaxolol 5-40 mg (long half-life)
 - With intrinsic sympathomimetic activity
 - Acebutolol 400-1200 mg
 - Non-selective (with alfa α-blocking activity)
 - Carvedilol 25-100mg






- Freemantle Nick, et al: β Blockade after myocardial infarction: systematic review and meta regression analysis BMJ 1999;318:1730
- Systematic review of randomised controlled trials.
- Subjects: Patients with acute or past myocardial infarction.
- Intervention: βBlockers compared with control.
- Main:outcome measures All cause mortality and non-fatal reinfarction









2012;308(13):1340-1349

Tab.4 Metaanalýza studií – kvantifikace účinku statinů⁴					
	Denní dávka statinu				
	5 mg	10 mg	20 mg	40 mg	80 mg
a) Absolutní pokles (mmol/l) LDL cholesterolu v séru					
Simvastatin	1,08	1,31	1,54	1,78	2,01
Lovastatin		1,02	1,3	1,77	2,15
Pravastatin	0,73	0,95	1,17	1,38	1,6
Fluvastatin	0,46	0,74	1,02	1,3	1,58
Atorvastatin	1,51	1,79	2,07	2,36	2,64
Rosuvastatin	1,84	2,08	2,32	2,56	2,8

b) Procentuální pokles (%) LDL cholesterolu v séru

, ,					
Simvastatin	23	27	32	37	42
Lovastatin		21	29	37	45
Pravastatin	15	20	24	29	33
Fluvastatin	10	15	21	27	33
Atorvastatin	31	37	43	49	55
Rosuvastatin	38	43	48	53	58

Barevně jsou vyznačeny ekvipotence dle Wenga a spol., 2010.⁵ Dávky statinů schopné snížit LDL cholesterol zhruba o 20–30 % jsou označeny bíle a dávky schopné snížit LDL cholesterol zhruba o 30–40 % jsou označeny tmavě zeleně.

Tab. 1 Cílové h	ab. 1 Cílové hodnoty cholesterolu a apolipoproteinu B				
	Populace obecně	Bez KVO, riziko ≥ 5 %, DM2 nebo DM1 s mikro- albuminurií	Přítomnost KVO		
Celkový cholesterol	< 5 mmol/l	< 4,5 mmol/l	< 4,0 mmol/l		
LDL cholesterol	< 3 mmol/l	< 2,5 mmol/l	< 2,0 mmol/l		
Non-HDL cholesterol	< 3,8 mmol/l	< 3,3 mmol/l	< 2,8 mmol/l		
Apolipo- -protein B	< 1,0 g/l	< 0,9 g/l	< 0,8 mmol/l		

Podle: Doporučení pro diagnostiku a léčbu dyslipidémií v dospělosti[,]

Tab. 2 Optimální hodnoty HDL cholesterolu a triglyceridů (stejné pro všechny kategorie rizika)

	Muži	Ženy
HDL cholesterol	> 1,0 mmol/l	> 1,2 mmol/l
Triglyceridy	< 1,7 mmol/l	< 1,7 mmol/l

Podle: Doporučení pro diagnostiku a léčbu dyslipidémií v dospělosti





FAKULTNÍ NEMOČNICE BRNO

Treatment - nitrates

- tolerance is a problem
- Nitroglycerin 0.4 mg spray (Aborts acute attacks; headaches, hypotension)
- Nitroglycerin 0.4–0.6 mg SL
- Nitroglycerin 0.1–0.6 mg/h patches Prophylactic therapy
- Isosorbide dinitrate 10–60 mg three times daily
- Isosorbide mononitrate 20 mg twice daily Take 7 h apart, slow release form – once daily









Treatment : ca blockers

Calcium Channel Blockers:

- Heart Rate Lowering
- Verapamil 120–480mg Heart-rate lowering; AV block, heart failure, constipation

Dihydroperidine Calcium Channel Blockers

- Amlodipine 5–10mg Least myocardial depression
- Felodipine 5–20mg High vascular selectivity







Alternative Diagnoses to Angina for Patients with Chest Pain

- Non-Ischemic CV: aortic dissection, pericarditis Pulmonary
 - pulmonary embolus
 - pneumothorax
 - Pneumonia, pleuritis
- Chest Wall / back pain
 - Costochondritis, fibrositis, rib fracture
 - sternoclavicular arthritis, herpes zoster
 - Spasm / injuries

Gastrointestinal

- Esophageal: esophagitis, spasm, reflux
- Biliary: colic, cholecystitis, choledocholithiasis, cholangitis
 - Peptic ulcer / Pancreatitis



Variant (Prinzmetal's) angina

Spasmus of vessels

Provocation during coronarography

(ergonovine=ergometrine intra arterially)





Ca blockers (verapamil)



Cíle po IM – sekundární prevence

- Zanechat kouření
- ✤ Kompenzace DM HbA1C < 6,5%</p>
- **Redukce nadváhy** (BMI \leq 30 kg/m2)
- ✤ TK < 130/80</p>
- ✤ TCH < 4,0 mmol/l</p>
- ✤ LDL < 2,0 mmol/l</p>
- TG <1,7 mmol/l, HDL > 1 (1,2 ženy) mmol/l





Treatment

- A = Aspirin and Antianginal therapy
- B = Beta-blocker and Blood pressure (BP)
- C = Cigarette smoking and Cholesterol
- D = Diet and Diabetes
- E = Education and Exercise






- Therapy (risk reduction of new MI)
 ASA (clopidogrel / ticlopidin) : -25%
 - BB risk reduction of new MI: -20% ?
 - ACEI risk reduction of new MI: -25
 - Statins risk reduction of new MI: -30%



CAD with heart failure









Courtesy of: MUDr. Roman Miklík, Ph.D.

CAD with heart failure Diagnosis: echo, CT scan, coronarography Therapy: revascularisation Therapy of heart failure diuretics BB ACEI

- ASA
- CRT / ICD



Arrhythmias - supraventricular

Atrial fibrillation

- Th: Beta blockers / amiodarone /(digoxin)
- Radiofrequency ablation

Sick sinus syndrome (SA arrest / brady / tachy syndrome)



FAKULTNÍ NEMOCNICI BRNO Atrio ventricular block

Pacemakers (VVI, DDD,CRT)









07:23:30

01-Dec 07:14:30

07:15:00 07:15:30 07:16:00

07:22:30

07:23:00

07:24:00


07:25:00

07:16:30 07:17:00 07:17:30 07:18:00 www 07:18:30 07:19:30 07:20:00 07:20:30 07:21:00 07:21:30 07:22:00

Multimeter Marken M

VE Run Length 20 beats (195 bpm01-Dec-2009 07:19:03

126 BPM at cursor



Thank You for You attention!



NASARYA

FAKULTNÍ NEMOCI BRNO